guest ::
| Home > Publications database > Gastric cancer patients less than 50 years of age exhibit significant downregulation of E-cadherin and CDX2 compared to older reference populations. > print |
| Home > Publications database > Gastric cancer patients less than 50 years of age exhibit significant downregulation of E-cadherin and CDX2 compared to older reference populations. > print |
| 001 | 128256 | ||
| 005 | 20240228135048.0 | ||
| 024 | 7 | _ | |a 10.1016/j.advms.2014.03.002 |2 doi |
| 024 | 7 | _ | |a pmid:24797991 |2 pmid |
| 024 | 7 | _ | |a 0067-6489 |2 ISSN |
| 024 | 7 | _ | |a 1427-941X |2 ISSN |
| 024 | 7 | _ | |a 1896-1125 |2 ISSN |
| 024 | 7 | _ | |a 1896-1126 |2 ISSN |
| 024 | 7 | _ | |a 1898-4002 |2 ISSN |
| 037 | _ | _ | |a DKFZ-2017-04273 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Schildberg, Claus Wilhelm |b 0 |
| 245 | _ | _ | |a Gastric cancer patients less than 50 years of age exhibit significant downregulation of E-cadherin and CDX2 compared to older reference populations. |
| 260 | _ | _ | |a Amsterdam [u.a.] |c 2014 |b Elsevier |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1523518364_23616 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a There is an increasing need to identify molecular markers, which can be used to prognosticate patient populations in gastric cancer. Whereas a significant number have been identified, very few have been characterized in the context of their ability to discriminate between young and old age groups in which a survival difference clearly exists.In this study, using immunohistochemistry, we evaluated three markers with proven involvement in gastric cancer. The p53 tumor suppressor, the cell adhesion glycoprotein epithelial cadherin (CDH1) and the caudal-related homeobox transcription factor (CDX2) all of these have important roles in the aetiopathogenesis and/or progression of gastric cancer.After adjustments for TNM stage, tumor grade, histopathological characteristics (Lauren classification), we found significant differences in the expression of these proteins, particularly E-cadherin and CDX2 between young and elderly patients. However, these differences did not amount to a significant difference in survival.This study demonstrates that the protein expression of p53, CDH1 and CDX2 significantly discriminates young patients with gastric cancer who have a better prognostic outlook from older patients, but this difference in expression does not contribute to a survival benefit. |
| 536 | _ | _ | |a 317 - Translational cancer research (POF3-317) |0 G:(DE-HGF)POF3-317 |c POF3-317 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 650 | _ | 7 | |a Biomarkers, Tumor |2 NLM Chemicals |
| 650 | _ | 7 | |a CDX2 Transcription Factor |2 NLM Chemicals |
| 650 | _ | 7 | |a CDX2 protein, human |2 NLM Chemicals |
| 650 | _ | 7 | |a Cadherins |2 NLM Chemicals |
| 650 | _ | 7 | |a Homeodomain Proteins |2 NLM Chemicals |
| 700 | 1 | _ | |a Abba, Mohammed Lawan |0 P:(DE-He78)54a8723466e5d487247f3d93d51c66bc |b 1 |u dkfz |
| 700 | 1 | _ | |a Merkel, Susanne |b 2 |
| 700 | 1 | _ | |a Agaimy, Abbas |b 3 |
| 700 | 1 | _ | |a Dimmler, Arno |b 4 |
| 700 | 1 | _ | |a Schlabrakowski, Anne |b 5 |
| 700 | 1 | _ | |a Croner, Roland |b 6 |
| 700 | 1 | _ | |a Leupold, Jörg Hendrik |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Hohenberger, Werner |b 8 |
| 700 | 1 | _ | |a Allgayer, Heike |0 P:(DE-He78)69067807288b48415ceb4abc43b9ad54 |b 9 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1016/j.advms.2014.03.002 |g Vol. 59, no. 1, p. 142 - 146 |0 PERI:(DE-600)2273671-2 |n 1 |p 142 - 146 |t Advances in medical sciences |v 59 |y 2014 |x 1896-1126 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:128256 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)54a8723466e5d487247f3d93d51c66bc |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-He78)69067807288b48415ceb4abc43b9ad54 |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-317 |2 G:(DE-HGF)POF3-300 |v Translational cancer research |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2014 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b ADV MED SCI-POLAND : 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
| 920 | 1 | _ | |0 I:(DE-He78)G360-20160331 |k G360 |l KKE Molekulare Onkologie solider Tumoren |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)G360-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|